{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:37:31Z","timestamp":1794670651428,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Umbilical cord blood transplantation (CBT) is accepted as an effective treatment for acute myeloid leukemia (AML), and reduced-intensity conditioning (RIC), rather than myeloablative conditioning (MAC) regimens allowed elderly patients to be treated safely. However, appropriate intensities of conditioning regimens are still unclear, especially for middle-aged patients. To compare outcomes after RIC and MAC regimens, we analyzed AML patients aged 16 years or older in the Japanese registry database, who underwent single cord unit CBT between 2010-2019. Median ages of the RIC group (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091353) and the MAC group (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20092101) were 59 and 51 years (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), respectively. 5-year overall survival (OS) after MAC was superior to that of RIC (38.3% vs 27.7%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) with lower incidence of relapse (33.9% vs 37.4%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.029) and better neutrophil engraftment (84.7% vs 75.9%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). Detailed subgroup analysis revealed that age at transplantation is the most important factor affecting 5-year OS in RIC and MAC. This analysis identified a threshold of 55 years, beyond which the superiority of MAC disappeared, irrespective of other factors such as disease status or performance status. In conclusion, RIC may be preferable for patients aged 56 or older in CBT for AML due to higher potential toxicities.\n                  <\/jats:p>","DOI":"10.1038\/s41409-025-02508-2","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:58:08Z","timestamp":1737439088000},"page":"458-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Myeloablative conditioning in cord blood transplantation for acute myeloid leukemia patients is efficacious only until age 55"],"prefix":"10.1038","volume":"60","author":[{"given":"Shinichiro","family":"Oshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-5093","authenticated-orcid":false,"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8959-6271","authenticated-orcid":false,"given":"Tadakazu","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5895-5382","authenticated-orcid":false,"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Hirabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-5926","authenticated-orcid":false,"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-0823","authenticated-orcid":false,"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigesaburo","family":"Miyakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1076-2338","authenticated-orcid":false,"given":"Satoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-244X","authenticated-orcid":false,"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5054-9104","authenticated-orcid":false,"given":"Yuta","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4795-121X","authenticated-orcid":false,"given":"Koji","family":"Nagafuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0393-4066","authenticated-orcid":false,"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-9775","authenticated-orcid":false,"given":"Masamitsu","family":"Yanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"2508_CR1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","volume":"118","author":"CG Brunstein","year":"2011","unstructured":"Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, et al. Alternative donor transplantation after reduced intensity conditioning: Results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118:282\u20138.","journal-title":"Blood"},{"key":"2508_CR2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/leu.2013.259","volume":"28","author":"A Ruggeri","year":"2014","unstructured":"Ruggeri A, Sanz G, Bittencourt H, Sanz J, Rambaldi A, Volt F, et al. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia working party of EBMT. Leukemia. 2014;28:779\u201386.","journal-title":"Leukemia"},{"key":"2508_CR3","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/leu.2015.98","volume":"29","author":"A Ruggeri","year":"2015","unstructured":"Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A, et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia. 2015;29:1891\u20131900.","journal-title":"Leukemia"},{"key":"2508_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1182\/blood-2013-02-453175","volume":"122","author":"KK Ballen","year":"2013","unstructured":"Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013;122:491\u20138.","journal-title":"Blood"},{"key":"2508_CR5","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1002\/sctm.20-0495","volume":"10","author":"X Zhu","year":"2021","unstructured":"Zhu X, Tang B, Sun Z. Umbilical cord blood transplantation: Still growing and improving. Stem Cells Transl Med. 2021;10:S62\u201374.","journal-title":"Stem Cells Transl Med"},{"key":"2508_CR6","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00277-020-04051-0","volume":"99","author":"M Yanada","year":"2020","unstructured":"Yanada M, Takami A, Yamasaki S, Arai Y, Konuma T, Uchida N, et al. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century. Ann Hematol. 2020;99:1351\u201360.","journal-title":"Ann Hematol"},{"key":"2508_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/sj.bmt.1703819","volume":"30","author":"A Gratwohl","year":"2002","unstructured":"Gratwohl A, Baldomero H, Passweg J, Urbano-Ispizua A, Baur A, Elvy P, et al. Increasing used of reduced intensity conditioning transplants: Report of the 2001 EBMT activity survey. Bone Marrow Transpl. 2002;30:813\u201331.","journal-title":"Bone Marrow Transpl"},{"key":"2508_CR8","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154\u201361.","journal-title":"J Clin Oncol"},{"key":"2508_CR9","doi-asserted-by":"crossref","unstructured":"Feinstein L, Sandmaier B, Maloney D, McSweeney PA, Maris M, Flowers C et al. Nonmyeloablative hematopoietic cell transplantation: Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann N Y Acad Sci. 2001;938:328\u201337.","DOI":"10.1111\/j.1749-6632.2001.tb03601.x"},{"key":"2508_CR10","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","volume":"97","author":"PA Mcsweeney","year":"2001","unstructured":"Mcsweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390\u2013400.","journal-title":"Blood"},{"key":"2508_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-1-4615-4987-1_5","volume":"101","author":"S Giralt","year":"1999","unstructured":"Giralt S, Khouri I, Champlin R. Non myeloablative \u2018mini transplants\u2019. Cancer Treat Res. 1999;101:97\u2013108.","journal-title":"Cancer Treat Res"},{"key":"2508_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/sj.bmt.1703355","volume":"29","author":"A Bacigalupo","year":"2002","unstructured":"Bacigalupo A. Special report Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transpl. 2002;29:191\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"2508_CR13","first-page":"6","volume":"111","author":"J Barrett","year":"2000","unstructured":"Barrett J, Childs R. Non-myeloablative stem cell transplant. Br J Haematol. 2000;111:6\u201317.","journal-title":"Br J Haematol"},{"key":"2508_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.bbmt.2014.11.009","volume":"21","author":"B Rio","year":"2015","unstructured":"Rio B, Chevret S, Vigouroux S, Chevallier P, F\u00fcrst S, Sirvent A, et al. Decreased Nonrelapse Mortality after Unrelated Cord Blood Transplantation for Acute Myeloid Leukemia Using Reduced-Intensity Conditioning: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant. 2015;21:445\u201353.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2508_CR15","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.bbmt.2011.01.007","volume":"17","author":"B Oran","year":"2011","unstructured":"Oran B, Wagner JE, DeFor TE, Weisdorf DJ, Brunstein CG. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2011;17:1327\u201334.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2508_CR16","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/j.bbmt.2020.07.025","volume":"26","author":"V Sheth","year":"2020","unstructured":"Sheth V, Volt F, Sanz J, Clement L, Cornelissen J, Blaise D, et al. Cord Blood Reduced-Intensity versus Myeloablative Conditioning in Cord Blood Transplantation for Acute Myeloid Leukemia (40-60 years) across Highly Mismatched HLA Barriers-On Behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT Biology of Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2020;26:2098\u2013104.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2508_CR17","doi-asserted-by":"publisher","first-page":"43027","DOI":"10.18632\/oncotarget.9599","volume":"7","author":"F Baron","year":"2016","unstructured":"Baron F, Ruggeri A, Beohou E, Labopin M, Sanz G, Milpied N, et al. RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. Oncotarget. 2016;7:43027\u201338.","journal-title":"Oncotarget"},{"key":"2508_CR18","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.bbmt.2017.01.084","volume":"23","author":"RB Salit","year":"2017","unstructured":"Salit RB, Oliver DC, Delaney C, Sorror ML, Milano F. Prognostic Value of the Hematopoietic Cell Transplantation Comorbidity Index for Patients Undergoing Reduced-Intensity Conditioning Cord Blood Transplantation. Biol Blood Marrow Transplant. 2017;23:654\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2508_CR19","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","volume":"27","author":"O Ringd\u00e9n","year":"2009","unstructured":"Ringd\u00e9n O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol. 2009;27:4570\u20137.","journal-title":"J Clin Oncol"},{"key":"2508_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-016-0347-1","volume":"9","author":"A Shimoni","year":"2016","unstructured":"Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J, et al. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. J Hematol Oncol. 2016;9:1\u201310.","journal-title":"J Hematol Oncol"},{"key":"2508_CR21","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1182\/bloodadvances.2022008706","volume":"7","author":"Y Akahoshi","year":"2023","unstructured":"Akahoshi Y, Tada Y, Sakaida E, Kusuda M, Doki N, Uchida N, et al. Novel risk assessment for the intensity of conditioning regimen in older patients. Blood Adv. 2023;7:4738\u201347.","journal-title":"Blood Adv"},{"key":"2508_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2009;15:367\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2508_CR23","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow TransplantMID: 7581076. 1995;15:825\u20138.","journal-title":"Bone Marrow TransplantMID: 7581076"},{"key":"2508_CR24","first-page":"250","volume":"28","author":"KM Sullivan","year":"1991","unstructured":"Sullivan KM. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250\u20139.","journal-title":"Semin Hematol"},{"key":"2508_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"key":"2508_CR26","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"2508_CR27","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3324\/haematol.2012.076042","volume":"98","author":"Y Atsuta","year":"2013","unstructured":"Atsuta Y, Kanda J, Takanashi M, Morishima Y, Taniguchi S, Takahashi S, et al. Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia. Haematologica. 2013;98:814\u201322.","journal-title":"Haematologica"},{"key":"2508_CR28","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH, et al. Revised Recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642\u20139.","journal-title":"J Clin Oncol"},{"key":"2508_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, & GRJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"2508_CR30","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1136\/bmj.322.7300.1479","volume":"16","author":"S Lewis","year":"2001","unstructured":"Lewis S. Clarke M. Forest plots: trying to see the wood and the trees. BMJ. 2001;16:1479\u201380.","journal-title":"BMJ"},{"key":"2508_CR31","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1602074","volume":"375","author":"F Milano","year":"2016","unstructured":"Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, et al. Cord-Blood Transplantation in Patients with Minimal Residual Disease. N. Engl J Med. 2016;375:944\u201353.","journal-title":"N. Engl J Med"},{"key":"2508_CR32","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1056\/NEJMoa041469","volume":"351","author":"V Rocha","year":"2004","unstructured":"Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia. N. Engl J Med. 2004;351:2276\u201385.","journal-title":"N. Engl J Med"},{"key":"2508_CR33","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1056\/NEJMoa041276","volume":"351","author":"MJ Laughlin","year":"2004","unstructured":"Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang M-J, Champlin RE, et al. Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia. N. Engl J Med. 2004;351:2265\u201375.","journal-title":"N. Engl J Med"},{"key":"2508_CR34","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1182\/blood-2006-04-020172","volume":"109","author":"S Takahashi","year":"2007","unstructured":"Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood. 2007;109:1322\u201330.","journal-title":"Blood"},{"key":"2508_CR35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1182\/blood-2015-04-642652","volume":"126","author":"Y Arai","year":"2015","unstructured":"Arai Y, Takeda J, Aoki K, Kondo T, Takahashi S, Onishi Y, et al. Efficiency of high-dose cytarabine added to CY\/TBI in cord blood transplantation for myeloid malignancy. Blood. 2015;126:415\u201322.","journal-title":"Blood"},{"key":"2508_CR36","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1038\/s41409-019-0571-8","volume":"54","author":"S Yano","year":"2019","unstructured":"Yano S, Yokoyama H, Yanada M, Mori J, Aoki J, Ohashi K, et al. Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission. Bone Marrow Transpl. 2019;54:2004\u201312.","journal-title":"Bone Marrow Transpl"},{"key":"2508_CR37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ajh.25705","volume":"95","author":"T Konuma","year":"2020","unstructured":"Konuma T, Kanda J, Inamoto Y, Hayashi H, Kobayashi S, Uchida N, et al. Improvement of early mortality in single-unit cord blood transplantation for Japanese adults from 1998 to 2017. Am J Hematol. 2020;95:343\u201353.","journal-title":"Am J Hematol"},{"key":"2508_CR38","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.immuni.2024.03.002","volume":"57","author":"M Ma","year":"2024","unstructured":"Ma M, Jiang W, Zhou R. DAMPs and DAMP-sensing receptors in inflammation and diseases. Immunity. 2024;57:752\u201371.","journal-title":"Immunity"},{"key":"2508_CR39","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.immuni.2019.08.011","volume":"51","author":"M Koyama","year":"2019","unstructured":"Koyama M, Mukhopadhyay P, Schuster IS, Henden AS, H\u00fclsd\u00fcnker J, Varelias A, et al. MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota. Immunity. 2019;51:885\u201398.e7.","journal-title":"Immunity"},{"key":"2508_CR40","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.bbmt.2013.05.003","volume":"19","author":"M Murata","year":"2013","unstructured":"Murata M, Nakasone H, Kanda J, Nakane T, Furukawa T, Fukuda T, et al. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: An analysis from the gvhd working group of the Japan society for hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1183\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2508_CR41","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3324\/haematol.2014.103655","volume":"99","author":"LS Muffly","year":"2014","unstructured":"Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99:1373\u20139.","journal-title":"Haematologica"},{"key":"2508_CR42","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3324\/haematol.2016.145847","volume":"101","author":"AS Artz","year":"2016","unstructured":"Artz AS, Logan B, Zhu X, Akpek G, Bufarull RM, Gupta V, et al. The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica. 2016;101:1426\u201333.","journal-title":"Haematologica"},{"key":"2508_CR43","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/bjh.18855","volume":"202","author":"T Jo","year":"2023","unstructured":"Jo T, Arai Y, Oshima S, Kondo T, Harada K, Uchida N, et al. Prognostic impact of complex and\/or monosomal karyotypes in post-transplant poor cytogenetic acute myeloid leukaemia: A quantitative approach. Br J Haematol. 2023;202:356\u201368.","journal-title":"Br J Haematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02508-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02508-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02508-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T12:19:20Z","timestamp":1743941960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02508-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2508"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02508-2","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was planned by the Adult AML Working Group of the JSTCT, approved by the data management committees of JSTCT and by the Institutional Review Board of Kyoto University Hospital. All methods were performed in accordance with the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}